

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Abbisko Cayman Limited**

**和譽開曼有限責任公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2256)**

## **VOLUNTARY ANNOUNCEMENT**

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd., a subsidiary of the Company, has completed the dosing of the first patient in China for its small-molecule PD-L1 inhibitor ABSK043.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK043 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Abbisko Cayman Limited**  
**Dr. Xu Yao-Chang**  
*Chairman*

Shanghai, September 27, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Dr. Xia Gavin Guoyao and Ms. Tang Yanmin as non-executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.*

## **Abbisko Therapeutics completed dosing of the first patient in China for its small-molecule PD-L1 inhibitor ABSK043**

27 September, 2022, Shanghai – Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**” hereafter) announced the completion of dosing of the first patient in China in the Phase I clinical trial in advanced solid tumors for oral PD-L1 inhibitor ABSK043.

ABSK043 is a highly selective and potent small molecule PD-L1 inhibitor with excellent oral bioavailability, which may fill the gap of PD-1/PD-L1 antibodies in clinical application, such as high cost, poor blood-brain barrier penetration and immunogenicity.

In preclinical studies, ABSK043 could effectively block PD-1/PD-L1 interaction and abolish the inhibition of T-cell induced by PD-L1. Its anti-tumor efficacy has been demonstrated in multiple mouse tumor models.

This trial (ABSK043-101) is the first clinical study of ABSK043 in China. Prior to this, first-in-human study of ABSK043 has been initiated in Australia in solid tumors. To date, multiple dosing cohorts have been completed in Australia with excellent PK/PD and safety profile observed.

### **About Abbisko Therapeutics**

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), is an oncology focused biopharmaceutical company founded in Zhangjiang, Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and around the world. The company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built up an extensive pipeline of 15 innovative small molecule programs primarily focused on precision oncology and immuno-oncology, including six clinical stage assets and nine pre-clinical stage assets. As of today, Abbisko Therapeutics has received 13 IND or clinical trial approvals in four countries and regions.

Please visit [www.abbisko.com](http://www.abbisko.com) for more information.

### **Forward-Looking Statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.